脊髓电刺激后阿片类药物使用变化:系统综述与荟萃分析
该系统综述与荟萃分析检索多个数据库至2024年7月1日,最终纳入43项研究。对12个月持续MME使用的22项研究比较(1666例)显示加权均数差为-18.06 MME(95%CI -24.41至-11.70;p<0.001);对12个月分类阿片类使用的24项研究比较(1527例)显示OR为0.47(95%CI 0.30至0.75;p=0.003)。结论认为脊髓电刺激与阿片剂量减少及停药 odds 增加相关,但证据确定性极低。
要点
- 脊髓电刺激植入后12个月阿片剂量平均减少18.06 MME。
- 12个月继续使用阿片类的 odds 降低(OR 0.47)。
- 上述结论基于极低确定性证据,解释需谨慎。
核心结论
- 脊髓电刺激与慢性疼痛患者12个月时阿片剂量减少及停药 odds 增加相关,但证据确定性极低。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、Cochrane Central Register of Controlled Trials和Scopus自建库至2024年7月1日,最终纳入43项研究。
主要发现
- 12个月持续MME使用的荟萃分析纳入22项研究比较(1666例),加权均数差为-18.06 MME(95%CI -24.41至-11.70;95%预测区间-38.29至2.17;p<0.001)。
- 12个月分类阿片类使用的荟萃分析纳入24项研究比较(1527例),OR为0.47(95%CI 0.30至0.75;95%预测区间0.10至2.11;p=0.003),表明继续使用阿片类的 odds 较低。
临床怎么用
- 对于慢性疼痛患者,脊髓电刺激可作为辅助减少阿片使用的策略,但需结合极低确定性证据个体化决策。
局限性
- 主要结论的证据确定性为极低(GRADE)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chronic pain is a leading cause of disability, and many affected patients rely on long-term opioid therapy despite its unfavorable adverse effect profile. Spinal cord stimulation is an established therapy for chronic pain that may secondarily reduce opioid consumption by providing sustained analgesia. OBJECTIVE: To quantify changes in opioid use following spinal cord stimulation implantation for the treatment of chronic pain through a systematic review and meta-analysis. DATA SOURCES: We conducted a comprehensive search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus from each database's inception to July 1, 2024. STUDY SELECTION: We included studies describing patients who underwent spinal cord stimulator implantation for the treatment of chronic pain. A total of 2,784 potential studies were identified and screened by multiple independent reviewers, yielding a final total of 43 studies included in the systematic review. DATA EXTRACTION AND SYNTHESIS: Data extraction was completed by multiple independent reviewers following Preferred Reporting Items for Systematic Reviews and Meta-Analysis and Meta-analysis Of Observational Studies in Epidemiology guidelines. A random effects model with Hartung-Knapp-Sidik-Jonkman adjustment was used to estimate pooled estimates. Certainty assessment was performed following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. MAIN OUTCOMES AND MEASURES: The primary outcomes were change in continuous opioid use (ie, morphine milligram equivalent (MME)) and categorical opioid use (yes/no) from preimplantation to 12 months following spinal cord stimulator implantation. RESULTS: Meta-analysis of 12 month continuous MME use comprising 22 study comparisons (1,666 individuals) revealed a weighted mean difference of -18.06 MME (95% CI -24.41 to -11.70; 95% prediction interval -38.29 to 2.17; p<0.001). Meta-analysis of categorical opioid use at 12 months comprising 24 study comparisons (1,527 individuals) revealed an OR of 0.47 (95% CI 0.30 to 0.75; 95% prediction interval 0.10 to 2.11; p=0.003), signifying lower odds of opioid continuation. CONCLUSIONS AND RELEVANCE: Spinal cord stimulation is associated with reduced opioid dose consumption and increased odds of opioid cessation at 12 months postimplantation compared with baseline in patients with chronic pain; however, both of these conclusions are supported by evidence of very low GRADE certainty. PROSPERO REGISTRATION NUMBER: CRD42024574921.
引用
- Soleymani H, Morsi M, Kopacz K, et al. Change in opioid use following spinal cord stimulation: a systematic review and meta-analysis. Reg Anesth Pain Med. 2026. PMID: 42120103. doi:10.1136/rapm-2026-107603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。